
-
ImmunityBio NasdaqGS:IBRX ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.
Location: 3530 John Hopkins Court, San Diego, CA, 92121, United States | Website: https://immunitybio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
3.057B
Cash
61.59M
Avg Qtr Burn
-92.54M
Short % of Float
56.33%
Insider Ownership
74.11%
Institutional Own.
9.24%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Anktiva (N-803) + BCG Details Cancer, Non-muscle invasive bladder cancer | Approved Update | |
Anktiva (N-803) + checkpoint inhibitors Details Non-small cell lung carcinoma, Cancer, Solid tumor/s | BLA Submission | |
PD-L1 t-haNK Details Pancreatic cancer, Cancer | Phase 2/3 Update | |
Anktiva (N-803) + AdHER2DC Details Cancer, Solid tumor/s, Endometrial cancer | Phase 1/2 Initiation | |
CAR-NK / CD19 t-haNK Details Cancer, Non-Hodgkin lymphoma | Phase 1 Data readout | |
N-803 (Anktiva), haNK and Avelumab Details Metastatic merkel cell carcinoma, Insomnia, Mood disorders, Liver transplant, Cancer | Failed Discontinued | |
hAd5-COVID-19 Details Vaccine, COVID-19 | Failed Discontinued |